This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Olmesartan medoxomil

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

4

Spl Product Data Elements

olmesartan medoxomil olmesartan medoxomil OLMESARTAN MEDOXOMIL OLMESARTAN HYDROXYPROPYL CELLULOSE (1600000 WAMW) HYPROMELLOSES LACTOSE MONOHYDRATE HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL, UNSPECIFIED TALC TITANIUM DIOXIDE STEARIC ACID WHITE TO OFF-WHITE ROUND 643 olmesartan medoxomil olmesartan medoxomil OLMESARTAN MEDOXOMIL OLMESARTAN HYDROXYPROPYL CELLULOSE (1600000 WAMW) HYPROMELLOSES LACTOSE MONOHYDRATE HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL, UNSPECIFIED TALC TITANIUM DIOXIDE STEARIC ACID WHITE TO OFF-WHITE ROUND 644 olmesartan medoxomil olmesartan medoxomil OLMESARTAN MEDOXOMIL OLMESARTAN HYDROXYPROPYL CELLULOSE (1600000 WAMW) HYPROMELLOSES LACTOSE MONOHYDRATE HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL, UNSPECIFIED TALC TITANIUM DIOXIDE STEARIC ACID WHITE TO OFF-WHITE OVAL 645

Application Number

ANDA205192

Brand Name

Olmesartan medoxomil

Generic Name

olmesartan medoxomil

Product Ndc

70771-1061

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1059-1 Olmesartan Medoxomil Tablets, 5 mg Rx only 100 TABLETS NDC 70771-1060-1 Olmesartan Medoxomil Tablets, 20 mg Rx only 100 TABLETS NDC 70771-1061-1 Olmesartan Medoxomil Tablets, 40 mg Rx only 100 TABLETS structured formula of olmesartan-image03 structured formula of olmesartan-image04 structured formula of olmesartan-image05

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.